Details of the Drug-Related molecule(s) Interaction Atlas

L-162234 Drug Info

CHEMBL292150; L-162234; SCHEMBL9377635; IVFMKMCSJZZCKV-UHFFFAOYSA-N; BDBM50035451; L008869; 5-n-Butyl-4-[[2''-[N-(tert-butoxycarbonyl)sulfamoyl]biphenyl-4yl]methyl]-2-[2-trifluoromethyl-phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; 4''-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid amide-N-carbonyoxylterbutyl; 4''-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid (2-tert-butoxycarbonyl)amide

Cross-matching ID

PubChem CID

9830680

TTD Drug ID

DMYSEBK

General Information of Drug (ID: DMYSEBK)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Angiotensin II receptor type-2 (AGTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[2]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[3]
EMA-401	DMYOUB6	Peripheral neuropathy	8C0Z	Phase 2	[4]
MP-157	DM5VXWO	Hypertension	BA00-BA04	Phase 1	[5]
PMID25416646-Compound-Figure5-E	DMYO7VH	N. A.	N. A.	Patented	[6]
Phenylpyridine derivative 3	DMDT5JI	N. A.	N. A.	Patented	[6]
1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	DMGYZQ2	N. A.	N. A.	Patented	[6]
Fonsartan	DM15LAP	Hypertension	BA00-BA04	Discontinued in Phase 2	[7]
L-158282	DMKSEIY	N. A.	N. A.	Discontinued in Phase 2	[8]
TAK-591	DM25DB4	Hypertension	BA00-BA04	Discontinued in Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-2 (AGTR2)	TTQVOEI	AGTR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity. J Med Chem. 2000 May 18;43(10):1993-2006.
2	The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
3	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
4	Clinical pipeline report, company report or official report of Spinifex.
5	As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
6	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
7	Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
8	Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
9	Clinical pipeline report, company report or official report of Takeda (2009).